Abstract: This disclosure relates to pharmaceutical compositions comprising one or more therapeutic agents selected from a SERPINE1 serine protease inhibitor, a histone acetyltransferase inhibitor, a histone deacetylase inhibitor, an insulin-like growth factor inhibitor, an anti-hypertensive agent, a topoisomerase II inhibitor, a tyrosine kinase inhibitor, an agent that downregulates growth factors or any combination thereof, and methods of treating fibrotic disorders, including keloid, pulmonary fibrosis, hepatic fibrosis, cardiac fibrosis, renal fibrosis, mediastinal fibrosis, retroperitoneal cavity fibrosis, bone marrow fibrosis, and/or scleroderma using the same. The disclosed methods can be accompanied by application of radiation and/or surgical resection. For treating keloids, the compositions can be formulated topically and do not cause systemic side effects. For treating fibrotic diseases of internal organs, the compositions can be administered systemically or delivered to the affected organs.

Abstract: Imatinib is approved and marketed in solid oral dosage forms which may be dispersed in water or apple juice for patients having swallowing difficulty. Dispersion of Imatinib solid dosage forms in apple juice may increase palatability and patient compliance but apple juice may not be available all the time for administration. Further, dispersion of Imatinib solid oral dosage forms may not administer correct and consistent dose of medicine every time. The present invention therefore provides liquid dosage forms of Imatinib which correctly and consistently administers correct dose of drug to the patients.

Abstract: Disclosed are composite compositions of B vitamins and C vitamins and the use of same in the preparation of a drug or health food for treating and/or preventing gastrointestinal conditions diseases related to deficiency of the gastrointestinal system motility. The composition comprises a vitamin B composition or an analogue or a derivative thereof and a vitamin C or an analogue or a derivative thereof.

Abstract: A sympathetic activation inhibitor and/or an ?1-adrenergic receptor inhibitor in preparing a medicine for treating dry eyes and belonging to the technical field of medicines for treating dry eyes, and a use of a sympathetic activation inhibitor and/or an ?1-adrenergic receptor inhibitor in preparing a medicine for treating or relieving dry eye syndrome. The medicine prepared by the use can antagonize an ?1-adrenergic receptor (including an ?1a-adrenergic receptor) or inhibit sympathetic activation, and can relieve and treat dry eye symptoms.

Abstract: Described herein is a combination therapy for the treatment of a cancer in a subject. In one aspect, the therapy comprises selinexor and one or more second anti-cancer agents.

Abstract: The present invention provides heterocyclylamine derivatives of Formula I: wherein the variables are defined herein, that modulate the activity of phosphoinositide 3-kinases (PI3Ks) and are useful in the treatment of diseases related to the activity of PI3Ks including, for example, inflammatory disorders, immune-based disorders, cancer, and other diseases.

Abstract: A compound of Formula (I), or a pharmaceutically acceptable salt thereof, is provided that has been shown to be useful for treating a PRC2-mediated disease or disorder: wherein R1, R2, R3, R4, R5, and n are as defined herein.

Abstract: This disclosure relates, at least in part, to a method of treatment. In one embodiment, the method of treatment comprises administering to a subject in need of such treatment a first therapeutic agent including compound (1): or a pharmaceutically acceptable salt thereof in combination with a second therapeutic agent, wherein the first therapeutic agent and the second therapeutic agent are administered either simultaneously or sequentially.

Abstract: In certain embodiments, the invention includes therapeutic methods of using a BTK inhibitor to treat solid tumor cancers by modulation of the tumor microenvironment, including macrophages, monocytes, mast cells, helper T cells, cytotoxic T cells, regulatory T cells, natural killer cells, myeloid-derived suppressor cells, regulatory B cells, neutrophils, dendritic cells, and fibroblasts.

Abstract: The disclosed compositions, systems and methods relate to compositions for human consumption and comprise a combination of paraxanthine and/or 1-methylxanthine and chlorogenic acid and optionally other compounds that modulate the effects of a combination of paraxanthine and/1-methylxanthine and chlorogenic acid. Further disclosed are methods of use of the foregoing compositions for improvement of at least one of cognitive performance, mood, and/or sleep.

Abstract: A powder including Valaciclovir or pharmaceutical acceptable salt or derivative thereof and an ion exchange resin. The Valaciclovir is in complex with the ion exchange resin forming Drug-Resin complex (DRC) particles, and each DRC particle comprises hydrogen bonds between the ion exchange resin and a cationic center of Valaciclovir. The ratio of Valaciclovir to the ion exchange resin in the DRC particle is 1:0.5. The powder further includes a suspending agent and a pH agent, and the suspending agent forms a film around each DRC particle and the film decreases interparticle attraction. The powder is configured to be reconstituted with an aqueous diluent as suspension for oral administration.

Abstract: The formulation disclosed herein has beneficial properties in enhancing the solubility and permeability (flux) of at least one of vardenafil, sildenafil, and/or related phosphodiesterase inhibitors or other ionizable compounds. In particular, the formulation confers beneficial properties for compounds in crossing the mucosal membrane, leading to an effective plasma drug concentration. In some embodiments, the formulation comprises an organic-aqueous solvent, which may include at least one of an alcohol, a polyether, diethylene glycol monoethyl ether, a medium chain glyceride, one or more saturated polyglycolyzed C8-C10 glyceride, and/or organic salts, or any combination thereof. In some embodiments, the formulation has a pH of about 3.5 to about 8.0. Also disclosed herein is a use for the formulation in administering one or more compound for the treatment of erectile dysfunction or other diseases, wherein the one or more compound is administered transmucosally (intranasally or sublingually).

Abstract: The present invention relates to a composition for preventing or treating metabolic diseases, containing 10-ethoxy-8-(morpholinomethyl)-2,3,4,6-tetrahydrobenzo[h][1,6]naphthyridin-5(1H)-one, a pharmaceutically acceptable salt thereof, a hydrate thereof, or a salt hydrate thereof as an active ingredient. Due to an adipocyte differentiation inhibitory effect, a fat accumulation inhibitory effect, an NAFLD inhibitory effect, and an NASH-induced fibrosis inhibitory effect of the composition, it is possible to prevent or treat metabolic diseases including nonalcoholic steatohepatitis (NASH), NASH-associated liver fibrosis, nonalcoholic fatty liver (NAFL), and NAFLD-associated liver fibrosis, fatty liver, and obesity.

Abstract: A PI3K-delta inhibitor or a pharmaceutically acceptable salt thereof for use in a method of treatment of pancreatic cancer in a patient, optionally wherein the method further comprises administration of an autotaxin (ATX) inhibitor or a pharmaceutically acceptable salt thereof.

Abstract: This invention relates to novel compounds and pharmaceutical compositions comprising. Compounds of the invention useful as modulators of Rho-associated protein kinase (ROCK), for example ROCK1 and/or ROCK2 inhibitors. Methods of treatment employing the compounds are also contemplated by the present invention. The compounds of the invention are useful in treating ROCK mediated diseases.

Abstract: The present invention relates to a composition for the purpose of preventing, alleviating, or treating a muscular disease, comprising an oxicam-based compound, wherein the composition strengthens muscles and increases muscle mass through the effects of promoting differentiation of myoblasts and increasing muscle fibers, and can, thereby, have a treatment effect for various muscular diseases and have muscle strengthening or motor performance increasing effects.

Abstract: The present invention relates to an inhibitor of H3K9 histone methyl transferase SUV39H1 for use in combination with at least one immune checkpoint modulator in the treatment of cancer.

Abstract: An object of the present invention is to provide a combination drug that has remarkably excellent preventive and/or therapeutic effects on polycystic kidney disease. The present invention provides a drug for preventing and/or treating polycystic kidney disease comprising a combination of tolvaptan or a prodrug thereof with a somatostatin derivative, and a method for treating polycystic kidney disease using this drug.

Abstract: Disclosed herein is a prophylactic or therapeutic agent for ocular fundus disease, especially diabetic retinopathy or age-related macular degeneration. The prophylactic or therapeutic agent for ocular fundus disease comprising: (S)-(-)-1-(4-fluoro-5-isoquinolinesulfonyl)-2-methyl-1,4-homopiperazine, a salt thereof, or a solvate thereof, as an active ingredient.

Abstract: Provided herein are methods for treating fibrosis (e.g. pancreatic fibrosis) in a subject. Some methods comprise administering to a subject having pancreatic fibrosis an effective amount of a CCK receptor inhibitor.

Abstract: Provided herein are treatment methods including administering a 5-hydroxytryptamine (HT)2C receptor agonist to a patient in need thereof. An exemplary method includes treating or preventing a 5-hydroxytryptamine (HT)2C receptor-associated disorder in a patient in need thereof, wherein the method comprises administering to the patient (R)—N-(2,2-difluoroethyl)-7-methyl-1,2,3,4,6,7-hexahydro-[1,4]diazepino[6,7,1-hi]indole-8-carboxamide (Compound 1), or a pharmaceutically acceptable salt thereof, wherein Compound 1, or a pharmaceutically acceptable salt thereof, is administered twice daily.

Abstract: Provided are an altrenogest injection and a preparation method and use thereof. The altrenogest injection includes 0.1-35 g altrenogest, 0.01-70 mL of polyethylene glycol, and a balance of an alcohol solvent per 100 mL of the altrenogest injection. The altrenogest injection can effectively inhibit estrus of sows, synchronize the estrus cycle of sows, and is more convenient and efficient to use, and the dosage is more precisely controllable. A single injection can effectively inhibit the estrus of sows for 6 to 12 days, which significantly reduces the labor costs for large-scale farms.

Abstract: The present invention is directed to the compound golexanolone or a pharmaceutically acceptable salt thereof for use in the treatment of fatigue or cognitive impairment, or a combination thereof, in a non-cirrhotic patient with a chronic liver disease, wherein the patient has a serum level of allopregnanolone which is 0.03 ng/ml or higher.

Abstract: The present disclosure relates to Compound (1) or a pharmaceutically acceptable salt thereof, for use in methods of treating major depressive disorder (MDD) with elevated anxiety in a subject in need thereof. The disclosure also relates to Compound (1) or a pharmaceutically acceptable salt thereof, for use in methods of treating postpartum depression (PPD) with elevated anxiety in a subject in need thereof.

Abstract: The present disclosure relates to Compound (1), or a pharmaceutically acceptable salt thereof, for use in methods of treating postpartum depression (PPD) in a human female subject during the subject's postnatal period, wherein the subject breastfeeds a child during the treatment period. The disclosure also relates to Compound (1), or a pharmaceutically acceptable salt thereof, for use in methods of treating major depressive disorder (MDD) in a human female subject, wherein the subject breastfeeds a child during the treatment period.

Abstract: The present disclosure provides a composition for ameliorating a skin tissue abnormality comprising a compound of formula (I) or an ester, oxide, pharmaceutically acceptable salt or solvate thereof.

Abstract: The embodiments disclose an active pharmaceutical ingredient, including (a) a T-cell-modulating cannabinoid or terpene, (b) a monocyte-modulating cannabinoid or terpene, and wherein the T-cell modulating cannabinoid or terpene is a CD4+ T-cell modulating cannabinoid or terpene, a CD8+ T-cell modulating cannabinoid or terpene, or a CD4+ and CD8+ T-cell modulating cannabinoid or terpene.

Abstract: A cannabinoid composition is provided that comprises a liquid carrier and a first lipid carrier comprising at least one cannabinoid, the first lipid carrier having a particle size from 10 nm to 100 nm. The cannabinoid composition further includes a second lipid carrier comprising at least one cannabinoid, the second lipid carrier having a particle size from 200 nm to 600 nm.

Abstract: A pharmaceutical composition, including a compound 1-(3-(3-N,N-dimethylaminocarbonyl)phenoxyl-4-mtrophenyl)-1-N ethyl-N,N?-bis(ethylene)phosphoramidate and at least one therapeutic agent including a chemotherapeutic agent or biological agent, and its medical use are provided.

Abstract: A pharmaceutical composition, and a preparation method therefor and an application thereof. The pharmaceutical composition comprises a spiro-aryl phosphorus oxide or a pharmaceutically acceptable salt thereof as an active ingredient and a pharmaceutically acceptable carrier. D90 of the spiro-aryl phosphorus oxide or the pharmaceutically acceptable salt thereof is in a range of 40.3 ?m to 79.6 ?m. The pharmaceutical composition has high content uniformity, a high dissolution rate, and high in-vivo bioavailability, and can be used for treating cancer.

Abstract: Disclosed are methods of treating a subject in need thereof comprising applying an alternating electric field, to a target site of the subject in need thereof; and administering a cancer associated fibroblast (CAF) inhibitor to the subject in need thereof. Disclosed are methods of reducing or preventing CAF activation comprising applying alternating electric fields, to a population of cells comprising one or more fibroblasts; and contacting a CAF activation inhibitor to the population of cells. Disclosed are methods of reducing CAF signaling comprising applying alternating electric fields, to a population of cells comprising one or more fibroblasts; and contacting a cancer associated fibroblast (CAF) signaling inhibitor to the population of cells.

Abstract: The present disclosure is directed to methods of treating patients with heart failure with reduced ejection fraction (HFrEF), with and without Type 2 diabetes, with an SGLT2 inhibitor, such as dapagliflozin. The methods disclosed herein can reduce the risk of a composite outcome of a first episode of worsening heart failure (hospitalization for heart failure or an urgent heart failure visit) or death from cardiovascular causes. Each of the three components of this composite outcome can also be reduced, as well as the total number of heart failure hospitalizations and deaths from cardiovascular causes. SGLT2 inhibitors, such as dapagliflozin, can also reduce a worsening of heart failure symptoms. The methods disclosed herein can also improve heart failure symptoms, health status, and quality of life.

Abstract: Disclosed herein are methods of treating HIBM in a subject comprising identifying subject in need thereof; and administering to the subject a compound, or a pharmaceutically acceptable salt, ester, amide, glycol, peptidyl, or prodrug thereof, wherein the compound is a compound that is biosynthesized in a wild type individual along a biochemical pathway between glucose and sialic acid, inclusive. Also disclosed herein are vectors comprising a nucleic acid sequence that encodes a polypeptide having at least 80% sequence identity to the sequence set forth in SEQ ID NO:2, recombinant cells comprising these vectors, and recombinant animals comprising the cells. In addition, methods of identifying a compound having therapeutic effect for HIBM are disclosed.

Abstract: Described are methods of treating a spaceflight-associated disease or condition, methods of reducing the effects of spaceflight or a low gravity environment, and methods of treating a subject in a low gravity environment. The methods comprise administration of a composition comprising one or more human milk oligosaccharides (HMOs).

Abstract: Provided is a novel active ingredient derived from locust bean and the use thereof. The present invention is a compound represented by the following formula (I) or a salt thereof, or a solvate thereof.

Abstract: Antioxidant composition for increasing the levels of vitamins and reducing oxidative damage in a subject; the composition comprises an active agent, containing polydatin and acetylcysteine.

Abstract: Compositions and methods for treatment of a condition associated with disease stem cells, and especially cancer stem cells are disclosed. In one aspect, a patient is treated with a stem cell differentiating agent and/or teratogenic pharmaceutical compound to induce one or more destructive pathways in the disease stem cells. Most typically, the destructive pathways include apoptotic pathways, necrotic pathways, and autophagy pathways.

Abstract: The current disclosure provides methods and compositions related to treating or preventing neutropenic fever (e.g., cancer therapy-induced neutropenic fever) and/or GVHD (e.g., HCT-related and/or neutropenic fever therapy-induced GVHD). In specific cases, it may be determined whether or not the subject is likely to develop or is at risk of developing neutropenic fever and/or GVHD, such as cancer therapy-induced neutropenic fever and/or HCT-related and/or neutropenic fever therapy-induced GVHD, based on the subject's gut microbiome.

Abstract: Disclosed are methods for treating cystic fibrosis where the method comprises administering to the subject an effective amount of an inhibitor selected from the group consisting of a sodium glucose co-transporter (SGLT) inhibitor, a Na+/K+-ATPase inhibitor, a SGLT/Na30/K+-ATPase dual inhibitor, and combinations thereof and a subeffective amount of one or more therapeutic agents selected from the group consisting of elexacaftor, tezacaftor, ivacaftor, and combinations thereof. Also disclosed are methods for treating CF characterized by a class I nonsense mutation in the CFTR gene where the method comprises administering to the subject an effective amount of a Na+/K+-ATPase inhibitor or a combination of an effective amount of a SGLT/Na+/K+-ATPase dual inhibitor and an effective amount of a Na30/K+-ATPase inhibitor.

Abstract: The current disclosure provides provides boosting intracellular NAD+ with nicotinamide riboside chloride (NR) to protect from cardiac dysfunction, NR being a natural NAD+ precursor that bypasses nicotinamide phosphoribosyltransferase (NAMPT) to stimulate intracellular NAD+ synthesis.

Abstract: Compounds, compositions and methods for preventing, treating or curing a coronavirus infection in human subjects or other animal hosts. In one embodiment, the compounds can be used to treat an infection with a severe acute respiratory syndrome virus, such as human coronavirus 229E, SARS, MERS, SARS-CoV-1, OC43, and SARS-CoV-2. In another embodiment, the methods are used to treat a patient infected with a Flavivirus, Picornavus, Togavirus, or Bunyavirus.

Abstract: The present invention is directed to compounds, compositions and methods for treating or preventing Zika virus. The compounds include pyrimidine and purine nucleosides and prodrugs thereof, including certain N4-hydroxycytidine nucleoside derivatives, sulfasalazine, and various entry inhibitors.

Abstract: The present invention relates to a compound of Formula (I): or a stereoisomer, solvate, tautomer or pharmaceutically acceptable salt thereof, wherein X, W1, W2, Y, Z, R1, R2 and R3 are as defined in the disclosure herein, for use in therapy, particularly for use in the treatment of cancer. The present invention also relates to methods of treating cancer comprising the administration of a compound of Formula (I) to a subject in need thereof, and to pharmaceutical compositions and kits comprising such compounds.

Abstract: This invention provides a designed short hairpin RNA (shRNA) containing RNA interference (RNAi) molecules. RNAi molecules hybridizes to a certain sequence of mRNA of TUBB2B. This invention develops a method of inhibiting TUBB2B expression in mammalian cell and a method of treating or controlling a cancer or tumor mediated by TUBB2B overexpression, including the step of administering a shRNA into a subject.

Abstract: Provided herein are methods of treating ST-elevation myocardial infarction (STEMI) and diseases of the digestion system using ?-1,3/1,6-D-glucan derived from mycellium extract of Ganoderma lucidum. Methods of treating ST-elevation myocardial infarction (STEMI) and diseases of the digestion system using a polysaccharide comprising ?-1,3/1,6-D-glucan are also provided.

Abstract: The present document is related to the field of dentistry and the treatment and prevention of oral inflammations and/or oral infections, and/or for use in endodontic treatment by using a chitosan gel, optionally in combination with a brush having bristles comprising chitosan.

Abstract: Provided herein are small molecule compounds, including non-anticoagulant heparan sulfate oligosaccharide molecules, having anti-inflammatory properties and capable of interacting with high mobility group box 1 (HMGB1) proteins in a manner sufficient to affect an interaction between the HMGB1 protein and a receptor for advanced glycation end products (RAGE). Also provided herein are methods of treating Paracetamol (APAP) overdose in subjects.

Abstract: Ligand Drug Conjugates of hydrophobically-modified auristatin F compounds that exhibit cytotoxic activities towards targeted cells, including abnormal cells such as cancer cells, that are MDR+ while also exhibiting bystander activities towards nearby cells having lower expression of the moeity targeted by the Conjugate.

Abstract: The present invention relates to a combination product comprising an antibiotic and at least one non-pathogenic microorganism for simultaneous, separate, or sequential use in preventing emergence of resistance to the antibiotic when treating a colonization and/or an infection caused by a bacterium that is susceptible to said antibiotic, wherein said at least one non-pathogenic microorganism is resistant to said antibiotic.

Abstract: A composition and method for addressing the presence of reactive oxygen species (ROS), reactive nitrogen species (RNS), and/or reactive sulfur species (RSS) abnormalities for the treatment, inhibition, and/or attenuation of disease states in a patient in need thereof. The method includes administering a sulfur-containing compound, such as sodium thiosulfate. A catalytic component can also be added to the composition to augment the rate of sodium thiosulfate action within the body.